The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for ...
56m
Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...
Recent studies reveal a concerning trend of vision loss among patients using Ozempic and other weight loss products, raising ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback